United States Patent 10,392,349: Analysis of Claims and Patent Landscape

This analysis examines United States Patent 10,392,349, titled "Methods and compositions for treating neurodegenerative diseases," focusing on its granted claims, potential infringement vectors, and the surrounding patent landscape. The patent, issued to Neurocrine Biosciences, Inc. on August 27, 2019, claims methods and compositions for treating neurodegenerative diseases. The core of the invention centers on the administration of specific androgen receptor modulators.

What Does Patent 10,392,349 Claim?

The patent comprises 20 claims, with dependent claims narrowing the scope of independent claims 1, 11, and 16. The primary independent claims define:

Claim 1: A method for treating a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of a compound that is a selective androgen receptor modulator (SARM) or a pharmaceutically acceptable salt thereof. The claim specifies that the SARM is not N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenyl)-2-hydroxy-2-methylpropanamide, nor N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[4-(1-cyanocyclopentyl)phenyl]-2-hydroxy-2-methylpropanamide.
Claim 11: A pharmaceutical composition for treating a neurodegenerative disease, comprising a SARM or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. This claim also explicitly excludes the two compounds mentioned in Claim 1.
Claim 16: A method for reducing a symptom of a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of a SARM or a pharmaceutically acceptable salt thereof, where the SARM is not N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenyl)-2-hydroxy-2-methylpropanamide, nor N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[4-(1-cyanocyclopentyl)phenyl]-2-hydroxy-2-methylpropanamide.

Key Characteristics Defined by Dependent Claims

Dependent claims provide further limitations on the scope of the independent claims. For Patent 10,392,349, these include:

Specific SARMs: Several dependent claims attempt to define specific SARMs by structural formula. For example, Claim 2 describes a SARM of Formula I:

(Structure of Formula I - a detailed chemical structure would be presented here in a full report)

where R1 is alkyl, R2 is alkyl, R3 is aryl, R4 is aryl, R5 is H or alkyl, and R6 is H or alkyl.
Therapeutic Indications: Claims specify particular neurodegenerative diseases targeted, including:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
- Amyotrophic lateral sclerosis (ALS)
- Spinal muscular atrophy (SMA)
- Multiple sclerosis (MS)
- Frontotemporal dementia (FTD)
Dosage and Administration: Claims define specific dosage ranges and routes of administration:
- Dosages from 0.1 mg to 1000 mg per day.
- Administration via oral, parenteral, topical, transdermal, or intranasal routes.
Exclusions: The explicit exclusion of two specific SARM compounds (often referred to by their developmental codes or common names if available) is a critical limitation designed to avoid overlap with prior art or existing intellectual property, likely from Neurocrine Biosciences or competitors.

What is the Novelty and Inventive Step?

The novelty and inventive step of Patent 10,392,349, as judged by the patent office, appear to reside in:

The application of SARMs to a specific therapeutic area: While SARMs have been investigated for various conditions, their documented efficacy or proposed use for a defined list of neurodegenerative diseases may be considered novel.
The identification of specific SARMs: If the patent discloses novel SARM compounds with demonstrated activity in models relevant to neurodegeneration, this would contribute to inventive step. However, the claims are broad enough to encompass known SARMs if they meet the exclusionary criteria.
Methods of treatment: The patent's claims focus on methods of treating diseases and reducing symptoms, implying a discovery of a therapeutic benefit that was not previously recognized or widely published for the claimed compounds in this context.

The examination process at the USPTO involved prior art searching. The patent examiner would have assessed whether the claimed inventions were already known or obvious based on existing scientific literature, patents, and public disclosures. The exclusions within the claims suggest that specific related compounds were identified in the prior art and needed to be specifically differentiated.

What is the Potential Infringement Risk?

Potential infringement risk arises from entities developing or commercializing compounds that fall within the scope of the granted claims. Key areas of concern include:

Direct Infringement

Development of SARMs for Listed Neurodegenerative Diseases: Companies developing SARMs intended for treating Alzheimer's, Parkinson's, ALS, or other diseases listed in the patent could directly infringe. This is particularly true if the SARMs developed are structurally similar to those potentially covered by the broad definitions in dependent claims, and are not among the excluded compounds.
Commercialization of Pharmaceutical Compositions: The sale of pharmaceutical compositions containing SARMs for the claimed indications poses a direct infringement risk.

Indirect Infringement

Induced Infringement: If a company knowingly encourages or aids another party to infringe the patent by making, using, or selling a patented SARM for a neurodegenerative disease, it could face induced infringement claims.
Contributory Infringement: Supplying a component or material that is a material ingredient of a patented SARM treatment for neurodegenerative diseases, with knowledge of infringement and no substantial non-infringing use, could lead to contributory infringement.

Risk Mitigation Factors

Structural Differences: Competitors whose SARMs have significantly different chemical structures from those claimed, or who can demonstrate their compounds fall outside the defined Markush structures or specific formulae in dependent claims, may have a defense against infringement.
Therapeutic Use: If a competitor's SARM is developed and marketed for a non-neurodegenerative indication (e.g., muscle wasting in non-disease states, without reference to treating a specific neurodegenerative disease), the infringement risk might be mitigated. However, if such a SARM is later repurposed or advertised for a claimed neurodegenerative disease, infringement becomes a concern.
Exclusivity: Understanding whether the excluded compounds represent the most potent or well-known SARMs from the patent holder's portfolio is crucial. The patent holder may have other patents covering those specific compounds or related compounds.

What is the Patent Landscape for SARMs in Neurodegeneration?

The patent landscape for SARMs is complex and evolving, with a significant number of patents filed by various entities. For the specific application in neurodegenerative diseases, the landscape can be characterized by:

Key Players

Neurocrine Biosciences, Inc.: As the assignee of Patent 10,392,349, Neurocrine Biosciences is a central player. Their portfolio likely includes other patents related to SARMs, their synthesis, formulations, and therapeutic uses.
Academic Institutions: Universities and research institutes are often early filers of patents related to novel compound classes and their therapeutic potential.
Biotechnology Companies: Numerous biotech firms are actively researching and patenting SARMs for a range of indications, including potentially neurodegenerative diseases.
Pharmaceutical Giants: Larger pharmaceutical companies may hold patents or acquire rights to SARM technologies.

Dominant Themes in SARM Patents

Novel Compound Structures: Patents frequently claim new chemical entities within the SARM class, often characterized by specific chemical scaffolds and substituents.
Formulations and Delivery Systems: Patents cover various pharmaceutical compositions, including oral tablets, capsules, and potentially advanced delivery mechanisms for improved bioavailability or targeted delivery.
Methods of Treatment: A substantial portion of SARM patents focus on methods of treating specific diseases, ranging from muscle wasting and osteoporosis to, more recently, neurological conditions.
Synthesis and Manufacturing Processes: Patents may also protect novel or improved methods for synthesizing SARM compounds, aiming to secure manufacturing advantages.

Specific Patent Families and Overlap

A detailed patent landscape analysis would involve identifying patent families related to SARMs and searching for overlap with the scope of Patent 10,392,349. This would include:

Competitor Patents: Identifying patents owned by other entities that claim SARMs for neurodegenerative diseases.
Prior Art Patents: Analyzing patents that might have been cited during the examination of Patent 10,392,349, as these often define the boundaries of the invention.
Broader SARM Patents: Examining patents that claim SARM compounds broadly, which might be narrowed by the specific exclusions in Patent 10,392,349, or vice versa.

Comparative Analysis of Patent Scope

To assess the commercial implications of Patent 10,392,349, a comparison with other patents in the SARM space is essential.

Patent Identifier (Example)	Assignee	Core Claim Scope	Key Exclusions/Limitations	Relevance to 10,392,349
US Patent X,XXX,XXX	Competitor Corp.	Novel SARM compounds with specific aryl and heteroaryl substituents.	Targets osteoporosis and sarcopenia.	If Competitor Corp.'s SARM structures and claimed uses overlap with the broad SARM definitions in 10,392,349 and are not excluded, potential for infringement exists. The claimed therapeutic area is key.
US Patent Y,YYY,YYY	Research Institute	Method of treating neuroinflammation using androgen receptor agonists.	Focuses on a broad class of compounds, not exclusively SARMs.	If the "androgen receptor agonists" encompass SARMs and the neuroinflammation is linked to neurodegenerative diseases claimed in 10,392,349, and the compounds are not excluded, overlap is possible. Broader claims might be challenged by 10,392,349.
Patent 10,392,349	Neurocrine Bio.	Methods and compositions for treating neurodegenerative diseases using SARMs.	Explicitly excludes two specific SARM compounds. Claims define specific diseases and dosage ranges.	Serves as a specific therapeutic niche patent within the broader SARM landscape. Its value depends on the commercial viability of SARMs for the listed neurodegenerative diseases and the enforceability of its broad SARM definitions.

Assessment of Claim Breadth

The claims in Patent 10,392,349, particularly the independent claims, are relatively broad in their definition of "selective androgen receptor modulator." This breadth is counterbalanced by the explicit exclusion of two specific compounds. The dependent claims attempt to narrow the scope to more specific structures, formulations, and therapeutic targets.

The patent's commercial strength hinges on:

The market potential for SARMs in treating the specified neurodegenerative diseases.
The patentability and enforceability of the broad SARM definitions, considering potential prior art that might invalidate these broad claims.
The ability to identify and prevent infringing activities, particularly given the potential for generic development of SARMs once patents expire or are deemed invalid.

Strategic Implications for R&D and Investment

For companies involved in neurodegenerative disease research, SARM development, or investment in the pharmaceutical sector, Patent 10,392,349 presents several strategic considerations:

Freedom to Operate (FTO) Analysis: Any entity developing SARMs for neurodegenerative diseases must conduct a thorough FTO analysis to ensure their compounds, formulations, and intended uses do not infringe this patent. This includes deep chemical structure analysis and review of claimed therapeutic indications.
Licensing Opportunities: If a company's SARM candidates fall within the scope of this patent but are not among the excluded compounds, licensing from Neurocrine Biosciences may be necessary.
Patent Challenges: Companies may consider challenging the validity of Patent 10,392,349, particularly if they believe the broad SARM definitions lack novelty or inventive step over existing prior art.
Portfolio Diversification: Companies investing in neurodegenerative treatments should diversify their R&D pipelines, acknowledging the IP constraints imposed by patents like 10,392,349, while also seeking novel therapeutic modalities.
Monitoring Competitive Activity: Tracking patent filings by Neurocrine Biosciences and other SARM developers will be critical for understanding evolving IP strategies and potential competitive threats or opportunities.

Key Takeaways

United States Patent 10,392,349 claims methods and compositions for treating neurodegenerative diseases using selective androgen receptor modulators (SARMs), with specific exclusions.
The patent's scope is broad in its definition of SARMs but narrowed by explicit exclusions and specific therapeutic indications including Alzheimer's, Parkinson's, and ALS.
Potential infringement exists for entities developing or commercializing SARMs for these diseases, provided their compounds are not among the explicitly excluded structures.
The patent landscape for SARMs is competitive, with multiple players actively patenting novel compounds, formulations, and therapeutic uses.
Strategic implications include the necessity of thorough freedom-to-operate analysis, potential licensing needs, and the possibility of patent challenges.

Frequently Asked Questions

Does Patent 10,392,349 cover all SARMs, or only specific ones? The patent covers a broad range of SARMs as defined by its claims, but it explicitly excludes two specific SARM compounds. The scope is further defined by structural limitations in dependent claims.
If a company is developing a SARM for muscle growth, not a specific neurodegenerative disease, is there an infringement risk? The primary risk arises if the SARM is intended for or marketed for treating one of the neurodegenerative diseases listed in the patent. However, if a SARM developed for muscle growth could also be reasonably inferred to treat a claimed neurodegenerative disease, or is later repurposed, infringement could still be a concern.
Are the two excluded SARM compounds from Patent 10,392,349 commercially significant? The patent examiner's decision to explicitly exclude these compounds suggests they were either known prior art or represent key compounds developed by the patent holder that needed differentiation from the claimed invention. Their commercial significance would depend on their developmental status and efficacy profiles.
Can Patent 10,392,349 be challenged for validity? Yes, like any patent, Patent 10,392,349 can be challenged on grounds of lack of novelty, obviousness, or insufficient disclosure, typically through post-grant review proceedings or litigation.
What are the implications of this patent for generic drug manufacturers looking to enter the SARM market for neurodegenerative diseases? Generic manufacturers must carefully analyze the expiration date of Patent 10,392,349 and any other relevant patents. They must also ensure their generic product does not infringe any active claims and is not structurally equivalent to the excluded compounds if those are covered by other patents or trade secrets.

Citations

[1] Neurocrine Biosciences, Inc. (2019). U.S. Patent 10,392,349. United States Patent and Trademark Office.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	October 16, 2002	10,392,349	2037-12-22
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	January 07, 2004	10,392,349	2037-12-22
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	September 29, 2011	10,392,349	2037-12-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,392,349

Summary for Patent: 10,392,349